SCN4B

SCN4B encodes the voltage-gated sodium channel β4 subunit (Navβ4), which modulates cardiac sodium channel gating and independently suppresses invasive cell migration through a channel-independent mechanism. Navβ4 associates with the Nav1.5 α-subunit (SCN5A) in cardiac cells, and the disease-associated L179F mutation causes an ~8-fold increase in late sodium current, establishing SCN4B as a long-QT syndrome (LQT10) gene (PMID:17592081). In non-excitable cells, the intracellular C-terminus of Navβ4 restrains RhoA activity, and loss of SCN4B promotes an amoeboid-mesenchymal hybrid invasive phenotype, tumor growth, and metastasis; this anti-invasive function is independent of sodium channel conductance and is accompanied by suppression of epithelial-mesenchymal transition (PMID:27917859, PMID:41685607). SCN4B expression is post-transcriptionally repressed by miR-424-5p and miR-3175 via direct 3′-UTR targeting in colorectal and prostate cancer cells, respectively, linking its downregulation to enhanced proliferation and metastasis (PMID:31785995, PMID:32833340).

1. 2007 High

   Whether the β4 subunit functionally modulates cardiac Nav1.5 was unknown; co-expression and electrophysiology showed that β4 associates with Nav1.5 and that the L179F mutation dramatically increases late sodium current, establishing SCN4B as a cardiac arrhythmia gene causing LQT3-type long-QT syndrome.

   Evidence Site-directed mutagenesis, HEK293 co-expression with SCN5A, patch-clamp electrophysiology

   PMID:17592081

   Open questions at the time

   • Structural basis for β4–Nav1.5 interaction not resolved
   • Whether other SCN4B variants cause arrhythmia through similar gating perturbations was untested
   • In vivo cardiac phenotype of L179F not established
2. 2016 High

   Whether SCN4B had functions beyond ion channel modulation was unknown; domain mapping and RhoA assays demonstrated that the β4 intracellular C-terminus restrains RhoA activity to suppress invasive cell migration, independent of sodium channel conductance, establishing a non-canonical tumor-suppressive role.

   Evidence shRNA knockdown, overexpression of full-length and C-terminal domain constructs, RhoA activity assay, in vivo xenograft and metastasis models in breast cancer cells

   PMID:27917859

   Open questions at the time

   • Direct molecular target connecting the β4 C-terminus to RhoA inhibition not identified
   • Whether this mechanism operates in non-cancer, non-excitable cells remains untested
   • Structural basis of C-terminus–RhoA pathway interaction unresolved
3. 2019 Medium

   Two arrhythmia-associated SCN4B variants (p.Gly8Ser and p.Ala145Ser) were shown to reduce steady-state Navβ4 protein levels, suggesting that loss-of-function via impaired protein stability is an additional disease mechanism beyond gating perturbation.

   Evidence Western blotting of variant proteins expressed in heterologous cells

   PMID:31020414

   Open questions at the time

   • No electrophysiological characterization of these variants was performed
   • Protein degradation pathway responsible for reduced expression not identified
   • Clinical phenotype–genotype correlation in families not reported
4. 2019 Medium

   How SCN4B is silenced in cancer was unclear; luciferase reporter assays established that miR-424-5p directly targets the SCN4B 3′-UTR in colorectal cancer, providing a post-transcriptional mechanism for SCN4B downregulation that promotes proliferation and metastasis.

   Evidence Luciferase 3′-UTR reporter assay, miR-424-5p mimic/inhibitor transfection, in vitro and in vivo xenograft assays in colorectal cancer cells

   PMID:31785995

   Open questions at the time

   • Whether miR-424-5p-mediated SCN4B repression operates through the RhoA pathway was not tested
   • Contribution of SCN4B suppression versus other miR-424-5p targets not deconvolved
   • Single lab finding without independent replication
5. 2020 Medium

   A second miRNA, miR-3175, was shown to directly target the SCN4B 3′-UTR in prostate cancer, with miR-3175 inhibition upregulating SCN4B and E-cadherin while suppressing invasion, reinforcing that post-transcriptional SCN4B silencing is a recurring cancer mechanism linked to EMT.

   Evidence Luciferase 3′-UTR reporter assay, RT-qPCR, Western blotting, proliferation and invasion assays in prostate cancer cells

   PMID:32833340

   Open questions at the time

   • Direct demonstration that SCN4B re-expression alone accounts for miR-3175 inhibitor phenotype is lacking
   • Mechanistic link between SCN4B levels and E-cadherin/N-cadherin regulation not established
   • Single lab without in vivo validation
6. 2026 Medium

   SCN4B overexpression in lung adenocarcinoma cells suppressed EMT markers (E-cadherin up, N-cadherin/Vimentin/Snail down), reduced viability and invasion, and promoted apoptosis, extending the tumor-suppressive role of SCN4B across a third cancer type and directly linking it to EMT suppression.

   Evidence Stable SCN4B overexpression in A549 and H1299 cells, Western blotting for EMT markers, CCK-8, wound healing, Transwell, and flow cytometry assays

   PMID:41685607

   Open questions at the time

   • Whether the anti-EMT effect depends on the C-terminus/RhoA mechanism was not tested
   • No in vivo tumor model confirmation
   • Downstream signaling pathway from SCN4B to Snail suppression not mapped
7. 2026 Medium

   Whether SCN4B has a neuronal function was unclear; Scn4b knockout in mice recapitulated Huntington's disease-like motor and cognitive deficits and striatal transcriptomic changes, while Scn4b overexpression in an HD mouse model rescued these phenotypes and restored striatal spiny projection neuron electrophysiology, implicating SCN4B in SPN excitability and HD pathogenesis.

   Evidence (preprint) Scn4b KO and overexpression in mouse models, snRNA-seq, behavioral assays, ex vivo electrophysiology

   PMID:41959367

   Open questions at the time

   • Preprint not yet peer-reviewed
   • Mechanism by which Scn4b loss alters SPN excitability (direct channel effect vs. transcriptomic cascade) not resolved
   • Relevance to human Huntington's disease patients not established

• The direct molecular mechanism by which the Navβ4 C-terminus inhibits RhoA, the structural basis of β4–Nav1.5 interaction, and whether the channel-dependent and channel-independent functions of SCN4B are coordinated in vivo remain unresolved.
• No structural model of the β4 C-terminus–RhoA interface exists
• In vivo cardiac phenotype of SCN4B mutations not characterized in animal models
• Integration of ion channel modulation and tumor-suppressive functions in the same tissue context has not been examined